Table 4.
The predictive value of PCDH17 methylation for the progression-free survival in ccRCC.
| Variable | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| Sex (Male vs. Female) | 1.325 | 0.805–2.316 | 0.3207 | |||
| Age (≥60 vs. <60) | 1.532 | 0.693–3.047 | 0.2031 | |||
| Pathological stage (T3 vs. T1/T2) | 2.968 | 1.853–9.335 | 0.0017 | 1.768 | 1.035–7.153 | 0.0136 |
| Fuhrman grade (III/IV vs. I/II) | 2.532 | 1.214–8.153 | 0.0075 | 1.541 | 0.793–6.832 | 0.0673 |
| Lymph node metastasis (N1 vs. N0) | 4.531 | 2.071–11.865 | <0.0001 | 3.652 | 1.872–9.461 | 0.0013 |
| PCDH17 methylation (M vs. U) | 3.973 | 1.795–8.792 | 0.0007 | 3.014 | 1.235–7.463 | 0.0028 |
HR – hazard ratio; M – methylated; U – unmethylated.